StocksMedium•9 November 2026•
1 min read
Kamada Stock Surges 7% on $50M Plasma Supply Deal and Upgraded Guidance
Key Facts
1Kamada shares rose 6.92% following the announcement of a new $50 million specialty plasma supply agreement.
2The company raised its annual earnings guidance supported by strong demand for specialty plasma products.
Kamada shares rose 6.92% following the announcement of a new $50 million specialty plasma supply agreement. Blockonomi reported that the company signed a three-year deal to supply normal source plasma through its U.S. operations, marking a significant commercial milestone in its strategy to expand supply capabilities.
The company raised its annual earnings guidance for 2026 supported by strong demand for specialty plasma products, now forecasting revenue between $205 million and $208 million. KMDA closed at $7.23 on November 6, 2026, after reaching a day high of $7.27 during that session.